Tarsus Pharmaceuticals, Inc. (TARS) stock
TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/309% above fair value
$80.28+3.39 (+4.41%)
Close on Nov 13, 2026Market cap $3.52BP/E –Yield 0.00%
Tarsus Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 93.0% | −7.0 |
| Q1 FY2026 | Mar 31, 2026 | 94.2% | −2.4 |
| Q2 FY2025 | Jun 30, 2025 | 93.9% | +0.0 |
| Q1 FY2025 | Mar 31, 2025 | 93.3% | −1.4 |
| Q1 FY2023 | Mar 31, 2023 | 100.0% | – |
| Q2 FY2022 | Jun 30, 2022 | 96.6% | – |
| Q1 FY2022 | Mar 31, 2022 | 93.9% | – |
| Q3 FY2021 | Sep 30, 2021 | 94.8% | – |
See a number that looks wrong?